Weiwei Chen

Title: Innovations of Weiwei Chen in Adenovirus Production

Introduction

Weiwei Chen is an accomplished inventor based in Tianjin, China. He has made significant contributions to the field of biotechnology, particularly in the production of adenoviruses. His innovative work focuses on enhancing the safety and efficiency of adenovirus production, which is crucial for vaccine development and other therapeutic applications.

Latest Patents

Weiwei Chen holds a patent for a cell strain designed to reduce the production of replication competent adenovirus. The patent, titled "Cell strain for reducing production of replication competent adenovirus, and construction method and use thereof," introduces the HEK293.CS cell strain. This cell line is engineered by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 cells. The resulting HEK293.CS cell line maintains its growth and virus production capabilities while eliminating the production of detectable replication competent adenovirus (RCA). This innovation is particularly beneficial for the mass culture of recombinant human type 5 adenovirus, thereby minimizing the risk of RCA production during the manufacturing of vaccines and antibodies.

Career Highlights

Weiwei Chen is currently employed at CanSino Biologics Inc., a leading company in the field of biopharmaceuticals. His work at CanSino Biologics has positioned him as a key player in the development of safe and effective viral vectors for vaccine production. His expertise in cell line engineering and adenovirus production has been instrumental in advancing the company's research and development efforts.

Collaborations

Throughout his career, Weiwei Chen has collaborated with notable colleagues, including Haiyan Cui and Lei Duan. These collaborations have fostered a productive research environment, leading to innovative solutions in the field of biotechnology.

Conclusion

Weiwei Chen's contributions to adenovirus production through his patented innovations demonstrate his commitment to advancing biopharmaceutical research. His work not only enhances the safety of viral vector production but also plays a vital role in the development of vaccines and therapeutic agents.